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A B S T R A C T
Adverse childhood experiences have been shown to aﬀect sensitivity to intranasal oxytocin administration, but
the neural mechanisms underlying this altered sensitivity are unclear. The aim of the current study was to
examine whether hippocampal abnormalities underlie the eﬀects of adversity on the response to oxytocin ad-
ministration. In a sample of healthy women (N=54, age M=19.63), we examined 1) the association between
hippocampal volume and experiences of emotional maltreatment and 2) whether hippocampal volume reduc-
tions inﬂuence the eﬀect of intranasal oxytocin administration on salivary oxytocin levels. There was no asso-
ciation between hippocampal volume and experiences of emotional maltreatment in the current study. However,
we found that larger hippocampal volume was related to a stronger increase in salivary oxytocin level after
intranasal oxytocin administration. The hippocampus may be a neural substrate underlying individual diﬀer-
ences in sensitivity to oxytocin administration.
1. Introduction
Adverse childhood experiences have protracted neurobiological ef-
fects and have been associated with changes in the oxytocinergic
system (Meaney, 2001). Research indicates that individuals with a
history of childhood adversity show lower oxytocin levels in cere-
brospinal ﬂuid (CSF) (Heim et al., 2009), plasma (Opacka-Juﬀry and
Mohiyeddini, 2012), and saliva (Riem et al., 2017, but see Bhandari
et al., 2014), and attenuated sensitivity to intranasal oxytocin admin-
istration. For example, stress-reducing eﬀects of intranasal oxytocin, as
reﬂected by cortisol decreases, are impeded in individuals with a his-
tory of childhood adversity (Meinlschmidt and Heim, 2007) and in
clinical groups with etiological factors rooted in childhood adversity
(Bakermans-Kranenburg and Van IJzendoorn, 2013). However, the
neural mechanisms underlying altered sensitivity to oxytocin adminis-
tration after childhood adversity are still unclear.
One neural substrate that may underlie altered sensitivity to oxy-
tocin administration is the hippocampus, a stress-sensitive brain region
that contains high densities of oxytocin receptors (Quintana et al.,
2017). The hippocampus is involved in modulating the responsiveness
of the hypothalamic–pituitary–adrenal (HPA) axis to stress. However,
exposure to childhood adversity results in prolonged elevated
glucocorticoids that damage the hippocampus (Meaney, 2001). More
speciﬁcally, early adverse experiences inhibit neurogenesis, and result
in a reduced number of hippocampal neurons and decreased gluco-
corticoid receptor expression (McEwen et al., 2015; McGowan et al.,
2009). These hippocampal changes in turn lead to impaired control of
the HPA axis, which leads to hyper- or hyporesponsiveness to stress
(Heim et al., 2008; McCrory et al., 2011). Indeed, research consistently
shows hippocampal volume reductions and altered stress reactivity in
individuals with a history of childhood adversity (Heim et al., 2008;
Riem et al., 2015), which may explain why these individuals are at risk
for the development of psychopathology (Heim et al., 2008).
A recent study with macaques demonstrated that early adversity
also disrupts oxytocin receptor expression in the hippocampus (Baker
et al., 2017). This down-modulation of the number of hippocampal
oxytocin receptors may be one of the mechanisms underlying reduced
sensitivity to intranasal oxytocin administration (Bakermans-
Kranenburg and Van IJzendoorn, 2017). The aim of the current study
was, therefore, to examine whether hippocampal abnormalities are
involved in individual diﬀerences in the response to oxytocin admin-
istration. In a sample of healthy women, we examined 1) the associa-
tion between hippocampal volume and experiences of emotional mal-
treatment and 2) whether hippocampal volume moderates the eﬀect of
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intranasal oxytocin administration on endogenous oxytocin levels as
assessed in saliva. We expected that women with a smaller hippo-
campus, possibly related to maltreatment, would show smaller in-
creases in salivary oxytocin than women with a larger hippocampus and
without emotional maltreatment experiences.
2. Methods
2.1. Participants
A total of 343 female undergraduate students from the Leiden
University participated in the ﬁrst phase of the study. In this phase, the
participants completed online questionnaires on their perception of
parenting experiences, including the childhood trauma questionnaire
(Bernstein et al., 2003), and some demographic details. One participant
was excluded due to random responses. Five females with children of
their own were also excluded. One hundred eighty six students parti-
cipated in the second phase of the study, which was designed to ex-
amine behavioral and cardiac responses to infant crying. Fifty-four
participants with scores ranging from low to high on the childhood
trauma questionnaire were selected to participate in the current mag-
netic resonance imaging (MRI) study. Half of the sample was randomly
drawn from the participants with the 25% highest scores on the
childhood trauma questionnaire and half of the sample was randomly
drawn from the remaining 75%. Participants were screened for MRI
contraindications, psychiatric or neurological disorders, hearing pro-
blems, pregnancy, and alcohol and drug abuse. Participants were ran-
domly assigned to the oxytocin or the placebo condition. (n=28
oxytocin, n=26 placebo). The mean age of the participants was 19.63
years (SD=1.43, range 18–27). 72.2% of the participants used oral
contraceptives. Permission for this study was obtained from the Ethics
Committees of the Institute of Education and Child Studies of Leiden
University and of the Leiden University Medical Centre.
2.2. Procedure
Participants were invited for an MRI study preferably in the luteal
phase of their menstrual cycle in order to control for inﬂuences of
menstrual cycle. During the luteal phase, plasma oxytocin levels are
lower (Salonia et al., 2005) and more responsive to stimulation such as
by nipple stimulation (Leake et al., 1984). Women were asked about the
date of their last menstruation and this information was used to sche-
dule the lab session. Menstrual phase and use of oral contraceptives
were balanced across the placebo and oxytocin group: 23 participants
in the oxytocin and 22 participants in the placebo group were in the
luteal phase, whereas 4 participants in the oxytocin group and 3 par-
ticipants in the placebo group were in the follicular phase. 21 partici-
pants in the oxytocin group and 18 participants in the placebo group
used oral contraceptives. For two participants it was not possible to
determine menstrual phase, because of use of hormonal intrauterine
device. They were instructed to abstain from alcohol and excessive
physical activity during the 24 h before the start of study, and from
caﬀeine on the data collection day. The session started with the ad-
ministration of a mood questionnaire and saliva collection to assess
baseline oxytocin levels. Afterwards, participants took 6 puﬀs of nasal
spray containing oxytocin (16 IU total) or 6 puﬀs of a placebo spray
under supervision of the experimenter. Eﬀects of 16 IU of oxytocin have
been reported in previous studies (Riem et al., 2011; Van IJzendoorn
et al., 2012). A previous study indicated no diﬀerence in salivary oxy-
tocin level increases after 16 or 24 IU oxytocin administration (Van
IJzendoorn et al., 2012). Drug administration was double-blind. Ap-
proximately 35min after nasal spray administration, a structural MRI
scan and functional scans were acquired during several paradigms.
Approximately 75min after nasal spray administration, a second saliva
sample was collected.
2.3. Mood
Mood was measured with the Positive Aﬀect Negative Aﬀect ques-
tionnaire (PANAS; see Supplemental Material).
2.4. Childhood trauma questionnaire
Participants completed the Dutch version of the Childhood Trauma
Questionnaire Short Form (CTQ-SF, Bernstein et al., 2003). CTQ-SF is a
measure of self-reported experiences of childhood abuse. Twenty-eight
items were used to assess experiences of physical abuse, emotional
abuse, sexual abuse, physical neglect, and emotional neglect. Each item
(e.g., “During my childhood I felt hated by family”) was rated on a 5-
point Likert scale ranging from never true to very often true. In the
current study we focused on the emotional abuse and emotional neglect
subscales because several studies with similar samples have shown that
experiences of emotional maltreatment are associated with dysregula-
tions of the oxytocin system (Riem et al., 2017; Van Ijzendoorn et al.,
2011). Moreover, sexual abuse is rather rare compared to emotional
maltreatment (Euser et al., 2013). The selection of participants was
based on these subscales, which therefore showed largest variability in
the current sample (see Table S1 for the means scores on each CTQ
subscale). An emotional maltreatment scale was created (α= .81) by
averaging the 10 items tapping into the emotional abuse and emotional
neglect dimensions. The mean score was 1.75 (SD=0.69) with scores
ranging from 1 to 4.40. A log transformation was applied to the emo-
tional maltreatment variable to approach a normal distribution.
2.5. Salivary oxytocin
At least 1 ml of unstimulated saliva was collected into cryotubes for
each sample using the passive drool method. Samples were immediately
frozen and were stored at -20 °C until batch assay. Level of oxytocin in
saliva was assayed using the commercially available EIA kit as per the
method previously described and used before (see Supplemental
Material). Prior to the enzyme immunoassay procedure, in keeping with
the manufacturer’s strong recommendation, an extraction step was
performed based on instructions accompanying the EIA kit available in
February 2011 (ADI-900-153, Enzo Life Science, Plymouth Meeting,
PA, USA).
2.6. MRI data acquisition and analysis
Scanning was performed with a standard whole-head coil on a 3-T
Philips Achieva TX MRI system (Philips Medical Systems, Best, the
Netherlands) in the Leiden University Medical Center. A T1-weighted
anatomical scan was acquired (ﬂip angle= 8°, 140 slices, voxel size
0.875×0.875 x 1.2mm). Volumes of the left and right hippocampus
were assessed using FIRST, part of FSL FMRIB’s Software Library,
http://www.FMRIb.ox.ac.uk/fsl (see Supplemental Material).
Hippocampal volumes were extracted after aﬃne registration to stan-
dard space and subcortical structure segmentation. Registrations and
segmentations were visually inspected, and no errors were observed.
After hippocampal volume extraction, the fslstats command was used to
assess volumes of the left and right hippocampus. The number of voxels
and mm3 of left and right hippocampus were obtained using the
threshold options to select out the single label numbers corresponding
to the left and right hippocampus (see https://fsl.fmrib.ox.ac.uk/fsl/
fslwiki/FIRST/UserGuide). Volumes of the left and right hippocampus
and total brain volume (mm3) (see Supplemental Material) were ex-
ported to SPSS.
2.7. Statistical analyses
A Repeated Measures ANOVA was performed with salivary oxytocin
as dependent variable, time (before and 75min after administration) as
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within-subject factor, group (oxytocin, placebo) as between-subject
factor and mean (left/right) hippocampal volume as covariate. Whole
brain volume, mood, time between nasal spray administration and
second saliva collection, oral contraceptive use, and menstrual cycle
(luteal, follicular) were entered as additional covariates in the analyses.
Another Repeated Measures ANOVA was performed, again with sali-
vary oxytocin as dependent variable, time as within-subject factor and
group as between-subject factor, but with emotional maltreatment as
covariate. Mood, time between nasal spray administration and second
saliva collection, oral contraceptive use, and menstrual cycle (luteal,
follicular) were entered as additional covariates in the analyses.
3. Results
Correlational analysis showed that mean hippocampal volume was
not signiﬁcantly related to emotional maltreatment (r= .01, p= .95)
or baseline oxytocin levels (r= .02, p= .92). Neither was there a
signiﬁcant correlation between emotional maltreatment and baseline
oxytocin levels (r = -0.10, p= .48). The repeated measures ANOVA
with salivary oxytocin levels as dependent variable showed signiﬁcant
main eﬀects of time (F(1,44)= 9.78, p= .003, partial ɳ2 = 0.18),
hippocampal volume (F(144)= 6.68, p= .013, partial ɳ2 = 0.13), and
group (oxytocin, placebo) (F(1,44)= 4.05, p= .050, partial ɳ2 =
0.08). In addition, there was a signiﬁcant time x group interaction (F
(1,44)= 4.11, p= .049, partial ɳ2 = 0.09) and a signiﬁcant time x
group x hippocampal volume (continuous) three-way interaction (F
(1,44)= 6.09, p= .018, partial ɳ2 = 0.12), indicating that the in-
crease in oxytocin levels after oxytocin administration was diﬀerent for
individuals with a smaller versus larger hippocampus. Hippocampal
volume was then dichotomized using a median-split (median=
3876.67) in order to interpret the three-way interaction. Fig. 1 shows
that individuals with a larger hippocampus showed a greater increase in
salivary oxytocin after oxytocin administration than individuals with a
smaller hippocampus. Mean oxytocin levels before and after oxytocin/
placebo administration are presented in Table 1. The interaction be-
tween hippocampal volume, oxytocin/placebo group and time re-
mained signiﬁcant when age was included as an additional covariate (F
(1,43)= 6.13, p= .017, partial ɳ2 = 0.13). The repeated measures
ANOVA with childhood emotional maltreatment as covariate did not
show a signiﬁcant main eﬀect of emotional maltreatment on salivary
oxytocin (F(1,45)= 1.07, p= .306, partial ɳ2 = 0.02). Neither was
there a signiﬁcant time x group x maltreatment three-way interaction (F
(1,45)= 1.31, p= .259, partial ɳ2 = 0.03). The analyses were re-
peated with the total score on the childhood trauma questionnaire, but
the results not did change (see supplemental material). Following a
reviewer suggestion, analyses were repeated separately for left and
right hippocampal volume in order to explore lateralization eﬀects, but
there were none. The time x group x maltreatment three-way interac-
tion was marginally signiﬁcant for both hemispheres (left: F
(1,45)= 3.69, p= .061, partial ɳ2 = 0.08; right: F(1,45)= 3.48, p=
.069, partial ɳ2 = 0.07.
4. Discussion
The current study shows that hippocampal volume is associated
with sensitivity to intranasal oxytocin administration. We found that
larger hippocampal volume was related to a stronger increase in sali-
vary oxytocin level after intranasal oxytocin administration. Our study
is the ﬁrst to demonstrate that eﬀects of intranasal oxytocin may be
dependent on hippocampal structure. The results are in line with those
of a previous study showing that hippocampal functional connectivity
plays a role in individual diﬀerences in sensitivity to intranasal oxytocin
(Fan et al., 2014). The hippocampus seems to be an important neural
moderator in the eﬀects of oxytocin, possibly because it contains a high
number of oxytocin receptors (Quintana et al., 2017). As a result,
variations in hippocampal structure may inﬂuence endogenous oxy-
tocin level increases after intranasal oxytocin administration.
A question that should be addressed in future research is how hip-
pocampal structure modulates the response to intranasal oxytocin. One
of our hypotheses is that hippocampal neuronal loss after childhood
adversity underlies reduced sensitivity to oxytocin administration in
individuals with adverse experiences. Another hypothesis is that epi-
genetic changes after childhood adversity result in reductions in oxy-
tocin receptor expression and inﬂuence sensitivity to intranasal oxy-
tocin. Adverse experiences stimulate vasopressin release and this may
lead to increased vasopressin receptor density and reduced oxytocin
receptor density and, thus, an imbalance between the oxytocin and
vasopressin system (Bakermans-Kranenburg and Van IJzendoorn,
2017). Hippocampal neuronal loss and reductions in oxytocin receptor
expression after childhood adversity may in turn impede the feedfor-
ward mechanism of the oxytocinergic system (Van IJzendoorn et al.,
2012; Churchland and Winkielman, 2012), with more production and
release of endogenous oxytocin with increased oxytocin levels after
Fig. 1. Mean (SE) oxytocin levels (pg/ml) before and after administration of the
oxytocin (upper panel) and placebo (lower panel) nasal spray for individuals
with a smaller (oxytocin N=14, placebo N=13) and a larger hippocampus
(oxytocin N=14, placebo N=13). For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of the article.
Table 1
Mean (SD) oxytocin levels (pg/ml) before and after administration of the
oxytocin and placebo nasal spray for individuals with a smaller (oxytocin
N=14, placebo N=13) and a larger hippocampus (oxytocin N=14, placebo
N=13).
Before administration After administration
M SD M SD
Oxytocin Smaller
hippocampus
5.21 2.21 200.23 241.28
Larger
hippocampus
5.18 2.35 689.64 581.78
Placebo Smaller
hippocampus
4.40 1.54 4.33 1.36
Larger
hippocampus
5.12 2.42 5.21 2.44
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administration, which may result in more short-lived oxytocin eﬀects or
even the absence of an eﬀect.
In the current study, experiences of emotional maltreatment did not
moderate the eﬀects of oxytocin. Neither was there an association be-
tween hippocampal volume and emotional maltreatment, perhaps be-
cause our sample consisted of healthy women without or with only
moderate experiences of emotional maltreatment, which is a limitation
of the study, or because the hippocampus underlies general individual
variability in oxytocin sensitivity, not necessarily dependent on mal-
treatment. Future studies should therefore examine neural moderators
of the eﬀects of oxytocin in clinical or maltreated samples, taking into
account diﬀerent types of maltreatment and, on the other hand, the
potentially protective role of positive parenting experiences (Luby
et al., 2012). Studying neural mechanisms underlying individual dif-
ferences in the response to oxytocin may shed more light on oxytocin’s
therapeutic potential, as it has been suggested to be only eﬀective in
(clinical) groups without adverse childhood experiences (Bakermans-
Kranenburg and Van IJzendoorn, 2013; Van IJzendoorn and
Bakermans-Kranenburg, 2016). In addition, future research should ex-
amine eﬀects of repeated intranasal oxytocin on endogenous oxytocin
levels and eﬀects up to a longer period of time after administration
because eﬀects of adversity may increase with time passed since ad-
ministration. Another limitation that should be noted is the use of self-
reported date of last menstruation to determine menstrual phase. Fur-
thermore, as it is still unclear how and whether intranasal oxytocin
enters the central nervous system, future studies should examine the
possible pathways through which oxytocin may reach the hippocampus
and other brain regions. A recent study with nonhuman primates
showed that intranasally administered oxytocin penetrates CSF, pos-
sibly via a direct pathway from the nasal cavity via the trigeminal or
olfactory nerves to CSF, although an indirect intranasal oxytocin de-
livery across the blood-brain barrier might also be possible (Lee
et al.,2018).
5. Conclusions
In conclusion, our study is the ﬁrst to suggest that hippocampal
volume modulates salivary oxytocin level increases after intranasal
oxytocin administration and indicates that the hippocampus is a po-
tential neural substrate underlying individual diﬀerences in sensitivity
to oxytocin administration.
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